Prosecution Insights
Last updated: October 02, 2026

Examiner: KWON, YONG SOK

Tech Center 1600 • Art Units: 1600 1613 1614 1625

This examiner grants 25% of resolved cases

Analysis

Yong Sok Kwon is an examiner in Tech Center 1600, specifically in Art Unit 1600. He has handled 61 resolved cases to date. The allowance rate is 24.6 percent, which is quite low and indicates a very challenging examination environment. Practitioners should be prepared for a rigorous process and a high likelihood of rejection. The 24.6 percent rate suggests that only a small portion of applications reach a grant under this examiner's review.

The interview lift is 42.7 percent, which is a significant positive indicator. This suggests that interviews are a very effective tool for overcoming rejections and moving a case toward an allowance. The median time to allowance is 1313 days. This is a long prosecution timeline, which is consistent with the low allowance rate. However, the 42.7 percent lift provides a critical strategic insight: an interview can substantially improve the odds of success. Practitioners should plan for an interview as a primary strategy to leverage this lift and potentially navigate the 1313 days of median pendency more effectively. The data shows that while the examiner is tough, he is responsive to direct engagement.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

24.6%
Allow Rate
-35.4% vs TC avg
72
Total Applications
+42.7%
Interview Lift
1313
Avg Prosecution Days
Based on 61 resolved cases, 2023–2026

Rejection Statute Breakdown

3.1%
§101 Eligibility
14.7%
§102 Novelty
39.9%
§103 Obviousness
22.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17792604 HERBICIDE COMPOSITIONS WITH AUXIN HERBICIDE MONOETHANOLAMINE SALTS WITH IMPROVED PROPERTIES Final Rejection MONSANTO TECHNOLOGY LLC
18134203 USE OF [(1R)-1-(2-CHLOROPHENYL)-2-(TETRAZOL-2-YL)ETHYL] CARBAMATE IN COMBINATION THERAPY Non-Final OA SK BIOPHARMACEUTICALS CO., LTD.
17640253 NOVEL COMPOSITIONS Final Rejection DSM IP ASSETS B.V.
17642595 PREMIX AND COMPOSITION AND METHODS OF PREPARING THE SAME Non-Final OA Conopco, Inc., d/b/a UNILEVER
18390923 MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION Non-Final OA Harrow IP, LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month